Search by Drug Name or NDC

    NDC 00074-2306-70 Rinvoq 15 mg/1 Details

    Rinvoq 15 mg/1

    Rinvoq is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is UPADACITINIB.

    Product Information

    NDC 00074-2306
    Product ID 0074-2306_b3ed4d84-05b2-41f8-9664-2e2fff13effc
    Associated GPIs 66603072007520
    GCN Sequence Number 080125
    GCN Sequence Number Description upadacitinib TAB ER 24H 15 MG ORAL
    HIC3 Z2Z
    HIC3 Description JANUS KINASE (JAK) INHIBITORS
    GCN 46822
    HICL Sequence Number 045955
    HICL Sequence Number Description UPADACITINIB
    Brand/Generic Brand
    Proprietary Name Rinvoq
    Proprietary Name Suffix n/a
    Non-Proprietary Name Upadacitinib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, EXTENDED RELEASE
    Route ORAL
    Active Ingredient Strength 15
    Active Ingredient Units mg/1
    Substance Name UPADACITINIB
    Labeler Name AbbVie Inc.
    Pharmaceutical Class Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA211675
    Listing Certified Through 2024-12-31

    Package

    NDC 00074-2306-70 (00074230670)

    NDC Package Code 0074-2306-70
    Billing NDC 00074230670
    Package 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-70)
    Marketing Start Date 2019-08-16
    NDC Exclude Flag N
    Pricing Information N/A